New SARS-CoV-2 Neutralizing Antibody enters Clinical Phase
18.12.2020 16:00:00 EET | Business Wire | Press release
Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim today announced the initiation of Phase 1/2a clinical investigation of BI 767551, a new SARS-CoV-2 neutralizing antibody. By combining UKK, UMR and DZIF’s expertise in virology, immunology and clinical investigation with Boehringer Ingelheim’s expertise in developing and manufacturing therapeutic antibodies, the partners developed BI 767551 as a potential new therapeutic and preventive/prophylactic option for fighting COVID-19.
Virus neutralizing antibodies are expected to become an important line of defense against SARS-CoV-2, complementing vaccines and nonpharmaceutical interventions. They are being investigated as a therapy option for individuals with mild or severe infections, but also as prevention or prophylaxis in non-infected people with a high risk of infection or at risk of serious outcomes. Directly delivering BI 767551 to the lung by inhalation has the potential to provide fast acting protection from virus infection in the respiratory tract.
The new antibody BI 767551 was derived from blood samples of recovered COVID-19 patients at UKK, examined for SARS-CoV-2 neutralization at UMR and developed further in collaboration with Boehringer Ingelheim. The clinical study will be led by Prof. Florian Klein and Prof. Gerd Fätkenheuer at UKK and Boehringer Ingelheim will supply the antibody. “With BI 767551, we aim to provide an effective option for preventing and treating COVID-19,” explains Prof. Florian Klein, Director of the Institute for Virology at the Cologne University Hospital and Principal Investigator at the DZIF.
”Monoclonal antibodies are a promising component in the fight against new viruses, such as the SARS-CoV-2. If this antibody turns out to be effective against COVID-19, this finding could be helpful in the current and also in future epidemics and pandemics. I am glad that we are able to assist in the development of this compound," says Prof. Stephan Becker, Director of the Institute of Virology at University of Marburg and Coordinator Emerging Infections, DZIF.
“We are excited to contribute to the development of BI 767551 in collaboration with our partners, with the aim to provide an innovative SARS-CoV-2 neutralizing antibody, combining a systemic with an inhaled route of administration” said Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit.
The Phase 1/2a studies (NCT04631705, NCT04631666) will evaluate the safety, pharmacokinetics and antiviral activity of the antibody. In Phase 1, the antibody will be administered to participants either with a single infusion or a single inhalation. If the antibody is well tolerated, late-stage confirmatory studies will be conducted.
Please click on the following link for ‘Notes to Editors’:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201218005318/en/
Contact information
Media Contacts
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com
Linda Ruckel
Senior Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
press@boehringer-ingelheim.com
Cologne University Hospital (UKK)
Christoph Wanko
Stellvertretender Pressesprecher
Stabsabteilung Unternehmenskommunikation
und Marketing
Tel.: +49 (221) 478 88757
christoph.wanko@uk-koeln.de
University of Marburg (UMR)
Dr. Gabriele Neumann
Leiterin der Stabsstelle Hochschulkommunikation
Pressesprecherin
Tel.: +49 6421 28-26118
Mail: gabriele.neumann@uni-marburg.de
German Center for Infection Research (DZIF)
Karola Neubert und Janna Schmidt
Pressestelle
Tel. : +49 6181 1170/1154
presse@dzif.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
InterSystems Honored with Four 2026 Best in KLAS Awards4.2.2026 19:00:00 EET | Press release
InterSystems, a creative data technology provider powering more than one billion health records globally, today announced it has received four Global 2026 Best in KLAS awards. The company earned a #1 ranking for Acute Care EHR in Asia, Oceania, and France, as well as for Shared Care Records in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204241673/en/ InterSystems earns four Best in KLAS awards for 2026 Best in KLAS is KLAS Research’s annual recognition of top-performing healthcare technology and services solutions, based entirely on feedback from healthcare provider organizations. Awards are given within defined software and services market segments evaluated by KLAS Research using a standardized methodology that reflects customer experience and performance. In addition to U.S. market segments, KLAS also recognizes top-performing solutions through its Global (Non-U.S.) Best in KLAS Awards, which are based on fe
Onego Bio Strengthens Board with Appointment of Dr. Antti Vasara4.2.2026 17:00:00 EET | Press release
Onego Bio, the food ingredient company producing non-animal egg protein through precision fermentation, today announced that Dr. Antti Vasara has joined its board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204881159/en/ Dr. Antti Vasara Dr. Vasara brings more than 25 years of global experience in science, technology, and commercial strategy. Most recently, he served as President and CEO of VTT Technical Research Centre of Finland, where he led one of Europe’s foremost deep tech research organizations. His distinguished career spans senior leadership roles in industry and innovation policy—including impactful work with Nokia and strategic contributions to European research and development initiatives. “Antti is one of the most respected leaders in science and innovation,” said Maija Itkonen, CEO of Onego Bio. “His deep understanding of technology commercialization and ecosystem level strategy will be inva
Andersen Consulting Expands Capabilities with Addition of SHMA4.2.2026 16:30:00 EET | Press release
Andersen Consulting enters into a Collaboration Agreement with SHMA, a leading actuarial and financial advisory firm headquartered in the UAE. SHMA is an actuarial consulting firm with nearly four decades of experience helping organizations navigate complexity, manage risk, and unlock opportunities through actuarial and insurance advisory, risk management, and valuation of End-of-Service Benefits (EOSB). Working with insurance companies, pension schemes, and other private and public organizations, SHMA helps clients build resilient organizations. “At SHMA, we keep quality, customized solutions, and genuine connection with people at the center of our mission,” said Shariq Sikander, director of SHMA. “Collaborating with Andersen Consulting provides us with the opportunity to extend our impact globally and expand our actuarial services beyond the MENA region, bringing innovative, client-focused solutions to organizations seeking practical and transformative approaches to their business ch
Energy Vault announces the Award of 100 MW / 870 MWh Long-Term Energy Service Agreement to its Development Partner in Australia4.2.2026 16:09:00 EET | Press release
Energy Vault Holdings, Inc. (NYSE: NRGV) (“Energy Vault”), a leader in sustainable, grid-scale energy storage solutions, and Bridge Energy Pty Ltd (“Bridge Energy”), an Australian developer bridging the gap between fossil fuels and renewable energy, today announced the Ebor Battery Energy Storage System (BESS) has been awarded a Long-Term Energy Service Agreement (LTESA) by AusEnergy Services. Located in Ebor, within the New England Region of New South Wales (NSW), the 100 MW / 870 MWh project will provide 8 hours of dispatchable capacity. The facility will play a critical role in advancing NSW’s renewable energy targets by providing essential grid firming capacity as aging coal generators retire. The system will charge during periods of excess renewable generation and discharge during peak demand, directly supporting the state’s transition to a decarbonized grid. Subject to obtaining the necessary contractual and regulatory approvals, Energy Vault plans to exercise its option to acqui
Boomi’s Market Momentum Accelerates as Enterprises Standardize on Its AI Activation Platform4.2.2026 16:00:00 EET | Press release
Boomi™, the leader in AI-driven automation, today announced that the company’s momentum in enterprise integration and agentic AI has reached a defining moment, driven by unmatched scale, independent analyst validation, proven customer outcomes, and ecosystem growth. With more than 30,000 customers worldwide — including over a quarter of the Fortune 500 — Boomi’s continued growth reflects the trust the world’s largest enterprises place in its platform.Today, customers rely on Boomi’s unique runtime architecture for mission-critical operations — including over 75,000 AI agents in production — executing billions of dollars in transactions with enterprise-grade reliability and resilience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204745523/en/ Boomi’s Market Momentum Accelerates as Enterprises Standardize on Its AI Activation Platform “Boomi is experiencing the strongest momentum in its history,” said Steve Lucas, Chairm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom